



# 13<sup>th</sup> Annual FDA/ACT-AD Allies Meeting

## *Common Threads: Learning from the Related Dementias*

The Accelerate Cures/Treatments for All Dementias (ACT-AD) Coalition’s 13th Annual FDA/ACT-AD Allies Meeting will explore the current therapeutic and research landscape for Alzheimer’s disease and related dementias. This virtual meeting will include presentations on cross-cutting issues between different forms of dementia. The meeting will also feature a forum for receiving updates on the National Institutes of Health’s (NIH) investment in Alzheimer’s disease and related dementias, the therapeutic pipeline of dementia therapies, recent research on the molecular underpinnings of dementia, academia’s vascular dementia biomarker project, and industry perspectives. A series of expert presentations will be followed by robust discussions with leaders from the National Institute on Aging at NIH and the Food and Drug Administration’s (FDA) Office of Neuroscience, world-leading dementia researchers and academics, and patient advocates.

### Agenda

---

<b>Welcome and Introductions</b>	10:30 AM – 10:40 AM (ET)
<b>The Quest to Develop Biomarkers for Vascular Cognitive Impairment</b> <i>Steven Greenberg, M.D., Ph.D., Harvard Medical School/Massachusetts General Hospital</i>	10:40 AM – 11:00 AM (ET)
<b>Discussion</b>	11:00 AM – 11:15 AM (ET)
<b>Federal Investment in Alzheimer’s Disease and Related Dementia Clinical Research</b> <i>Suzana Petanceska, Ph.D., and Laurie Ryan, Ph.D., National Institute on Aging</i>	11:15 AM – 11:55 PM (ET)
<b>Discussion</b>	11:55 PM – 12:15 PM (ET)
<b>Lunch Break</b>	12:15 PM – 12:30 PM (ET)
<b>An Exploration into the Dementia Therapeutic Pipeline</b> <i>Jeffrey Cummings, M.D., Sc.D., University of Nevada, Las Vegas</i>	12:30 PM – 12:50 PM (ET)

<b>Discussion</b>	12:50 PM – 1:05 PM (ET)
<b>Research into Molecular Underpinning of Dementia</b> <i>David Bennett, M.D., Rush Alzheimer's Disease Center</i>	1:05 PM – 1:35 PM (ET)
<b>Discussion</b>	1:35 PM – 1:50 PM (ET)
<b>Dementia Clinical Development Questions and Challenges: Industry Perspective</b> <i>Samantha Budd Haeberlein, Ph.D., Biogen, Sanjay Dube, M.D., Avanir, and Eva Kohegyi, M.D., M.S., Otsuka</i>	1:50 PM – 2:25 PM (ET)
<b>Closing Remarks</b>	2:25 PM – 2:30 PM (ET)